Clinical Trials: Clinical Trial Operations & Compliance

Breaking Down CTD Modules: FDA and ICH Perspectives

Posted on digi By digi

The Common Technical Document (CTD) is the globally harmonized structure for regulatory submissions, and the electronic CTD (eCTD) has become the mandatory format for US FDA submissions under the Electronic Submissions Gateway (ESG). CTD modules organize regulatory information into five core sections, ensuring consistency, completeness, and efficient review by regulators. For sponsors, correct structuring of modules is critical, as deficiencies often result in technical rejections, Refuse-to-File (RTF) decisions, or inspection findings. The FDA and ICH provide clear expectations on module content, structure, and lifecycle management.

Click to read the full article.

Clinical Trial Operations & Compliance, Regulatory Submissions (CTD/eCTD)

Training and Competency in Clinical Trial Logistics

Posted on digi By digi

Clinical trial logistics involve complex processes—storage, distribution, accountability, and destruction of investigational medicinal products (IMPs). For US sponsors, the FDA requires that all staff handling trial supplies are adequately trained and qualified. Inadequate training often leads to errors in IMP accountability, temperature excursion management, and documentation, which can result in regulatory findings. Competency in logistics is not optional; it is a compliance requirement.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

eCTD Lifecycle Management: Compliance and Operational Challenges

Posted on digi By digi

The electronic Common Technical Document (eCTD) is the mandatory format for US FDA submissions, including INDs, NDAs, and BLAs, through the Electronic Submissions Gateway (ESG). Unlike static submissions, eCTD operates as a sequence-based lifecycle, where new, replaced, or withdrawn documents are tracked to maintain submission history. For US sponsors, FDA technical validation ensures submissions are consistent, traceable, and review-ready. Poor lifecycle management results in technical rejection, delayed reviews, or inspection findings. EMA, ICH, and WHO have also harmonized requirements, making lifecycle oversight critical for global submissions.

Click to read the full article.

Clinical Trial Operations & Compliance, Regulatory Submissions (CTD/eCTD)

Common Issues in CTD/eCTD Submissions and How to Address Them

Posted on digi By digi

The Common Technical Document (CTD) and electronic CTD (eCTD) form the global standard for regulatory submissions to agencies including the FDA, EMA, and Health Canada. For US sponsors, the FDA requires eCTD format for most IND, NDA, and BLA submissions under the Electronic Submissions Gateway (ESG). Despite harmonization under ICH M4 guidelines, many submissions face technical rejections or regulatory queries due to common, avoidable issues. Understanding these pitfalls and implementing preventive measures is crucial for maintaining compliance and avoiding costly delays.

Click to read the full article.

Clinical Trial Operations & Compliance, Regulatory Submissions (CTD/eCTD)

Courier Oversight in Clinical Trial Logistics

Posted on digi By digi

Couriers form the critical link between depots and clinical trial sites—or in direct-to-patient (DTP) models, between depots and patients’ homes. For US sponsors, courier oversight is a high-risk area under FDA inspections, with deficiencies leading to Form 483s and delayed trial timelines. Couriers manage temperature-sensitive products, chain-of-custody documentation, and timely delivery, making them compliance-critical partners rather than just logistics providers.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Stability Data in CTD Submissions: Regulatory Expectations

Posted on digi By digi

Stability data is a cornerstone of Module 3 in CTD submissions, providing evidence that an investigational product maintains its intended quality, safety, and efficacy throughout its shelf life. For US sponsors, the FDA requires stability studies to align with 21 CFR Part 211.166 and ICH Q1A–Q1E guidelines. These data support expiry dating, storage conditions, and quality assurance of the drug substance and product. Inadequate or incomplete stability data is one of the most common deficiencies cited by the FDA and EMA in regulatory reviews.

Click to read the full article.

Clinical Trial Operations & Compliance, Regulatory Submissions (CTD/eCTD)

Module 5: Clinical Study Reports in CTD Submissions

Posted on digi By digi

Module 5 of the Common Technical Document (CTD) houses clinical study reports (CSRs), case report forms (CRFs), and datasets, making it one of the most scrutinized sections by regulators. For US sponsors, the FDA requires Module 5 to be comprehensive, accurate, and aligned with 21 CFR Part 312 and ICH E3 Guidance on Structure and Content of Clinical Study Reports. This module directly informs regulatory decisions on safety and efficacy. Incomplete or poorly organized submissions often lead to Refuse-to-File (RTF) decisions or significant review delays.

Click to read the full article.

Clinical Trial Operations & Compliance, Regulatory Submissions (CTD/eCTD)

Depot Management and Oversight in Clinical Trial Logistics

Posted on digi By digi

Depots are central nodes in the clinical trial supply chain, responsible for storing, distributing, and reconciling investigational medicinal products (IMPs). For US sponsors, the FDA requires that depots operate under Good Distribution Practice (GDP) and maintain full accountability for IMP disposition. Failures in depot oversight can result in temperature excursions, data integrity issues, and regulatory citations. As clinical trials expand globally, depot networks often involve multiple vendors, increasing oversight complexity.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Oversight of CRO Vendor Qualification in Clinical Trials

Posted on digi By digi

Contract Research Organizations (CROs) play a pivotal role in clinical trial execution, from monitoring to data management and pharmacovigilance. For US sponsors, 21 CFR Part 312.50 places ultimate responsibility for trial conduct and data integrity on the sponsor, regardless of outsourcing. This makes vendor qualification a regulatory imperative. The FDA has repeatedly cited sponsors in Form 483s and Warning Letters for failing to adequately qualify CROs. EMA, ICH GCP (E6[R2]), and WHO guidelines similarly stress sponsor accountability for vendor oversight.

Click to read the full article.

Clinical Trial Operations & Compliance, Vendor Oversight & CRO Compliance

Sponsor Oversight of CROs: Regulatory Expectations and Best Practices

Posted on digi By digi

The delegation of trial conduct to Contract Research Organizations (CROs) is common across the pharmaceutical industry. However, sponsors remain ultimately responsible for compliance with 21 CFR Part 312 in the United States, regardless of outsourcing. The FDA has repeatedly reinforced that delegation does not diminish sponsor obligations for subject safety, data integrity, and adherence to Good Clinical Practice (GCP). ICH E6(R2) further stresses sponsor accountability for vendor oversight. EMA and WHO echo similar expectations, requiring sponsors to establish risk-based oversight mechanisms for all outsourced functions.

Click to read the full article.

Clinical Trial Operations & Compliance, Vendor Oversight & CRO Compliance